Bausch+Lomb Results Presentation Deck
Xiidra + Miebo: Holistic Approach to DED Treatment
Dry Eye Disease Opportunity
Multi-factorial disease,
requires different treatment options
Large $1.7B U.S. market¹,
DED affects more than 38M Americans²
DE 20 AY
BAUSCH+ LOMB
Miebo
Joel..crchenloctine
ophthalmic solution
HOE STEDILE
Miebo.
SER
Ax only
Far Topical
Ophthalmic Use
Maltple-dese
container
Underdiagnosed and undertreated,
~96% of U.S. patients not treated with an Rx product²
Highly promotionally sensitive,
driven by field force, ECP and DTC campaigns
3rmi
6341
xiidra
ophthalmic solution S
&
Bausch + Lomb Approach
Full treatment paradigm of inflammatory
and evaporative dry eye in one portfolio
Leadership in DED category elevates
relevance to physicians and managed care
Leverage portfolio investment to
drive disease awareness
Largest field force with highest share
of voice in DED Rx market
1. Ophthalmology Company & Drug Insights, Clarivate /DRG.
2. Downs P. 2020 Dry Eye Products Market Report: A Global Analysis for 2019 to 2025. Market Scope; 2020. | Lemp, MA, Crews, LA, Bron AJ. (2012). Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Cohort: a
retrospective study. Cornea, 31(5), 472-478. 2012;31(5):472-478. doi:10.109/ICO.0b013e318225415a.
16View entire presentation